The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases

Leave a Comment

High costs of complying with drug development regulations slow progress and contribute to high drug prices and, hence, mounting health care costs.  If it is exorbitantly expensive to bring new therapies to approval, fewer agents can be developed with available resources, impeding the emergence of urgently needed treatments and escalating prices by limiting competition.  Excessive regulation produces numerous speed bumps on the road to drug authorization.  Although an explosion of knowledge could fuel rapid advances, progress has been slowed worldwide by inefficient regulatory and clinical research systems that limit access to therapies that prolong life and relieve suffering.  We must… more…

To benefit from new cancer drugs, reform the regulatory regime

To benefit from new cancer drugs, reform the regulatory regime

Leave a Comment

Dr. David J. Stewart is a professor of medicine and head of the Division of Medical Oncology at the University of Ottawa; John-Peter Bradford is a member of the Research Advisory Group of the Canadian Partnership Against Cancer and the Cancer Care Committee of the Ottawa Regional Cancer Foundation. We are concerned Canadians who have been impacted deeply by cancer. One of us (Stewart) is a cancer physician who has seen far too many patients die; the other (Bradford) is a cancer survivor who has recently lost his beloved wife to cancer. She was directly affected by the issues we… more…